Cited 0 times in
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, JJ | - |
dc.contributor.author | Kim, SY | - |
dc.contributor.author | Chung, HC | - |
dc.contributor.author | Lee, KH | - |
dc.contributor.author | Song, HS | - |
dc.contributor.author | Kang, WK | - |
dc.contributor.author | Hong, YS | - |
dc.contributor.author | Choi, IS | - |
dc.contributor.author | Lee, YY | - |
dc.contributor.author | Woo, IS | - |
dc.contributor.author | Choi, JH | - |
dc.date.accessioned | 2010-12-17T05:42:25Z | - |
dc.date.available | 2010-12-17T05:42:25Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/672 | - |
dc.description.abstract | PURPOSE: This study was conducted to evaluate the safety and efficacy of S-1 and paclitaxel combination therapy for patients with advanced gastric cancer.
METHODS: Eligible patients had previously untreated advanced or relapsed gastric cancer with measurable lesion(s) and an ECOG PS of 0-2. Treatment consisted of S-1 35 mg/m(2) p.o. b.i.d. on days 1-14 followed by a 7-day off plus paclitaxel 70 mg/m(2) i.v. on days 1 and 8 of a 21-day cycle. RESULTS: Fifty-six patients (M/F = 37/19) were enrolled. The median age was 59 years. The median number of cycles administered was six (range 1-18). Out of the 53 patients evaluated, there was 1 (1.9%) CR, 20 (37.7%) confirmed PRs, 5 (9.4%) unconfirmed PRs, 21 (39.6%) SDs, and 6 (11.3%) PDs. The objective tumor response was 39.6%. The median time to progression was 29 weeks. The median survival was 51 weeks. All 56 patients were assessed for treatment safety. The treatment was well tolerated with grade 3/4 neutropenia in 20%/13%, grade 3 febrile neutropenia in 7%, grade 2/3 diarrhea in 9%/4%, vomiting in 11%/0%, stomatitis in 4%/4%, and neuropathy in 4%/0% of patients. CONCLUSIONS: S-1 and paclitaxel combination treatment is an effective regimen with a favorable toxicity profile in patients with advanced gastric cancer. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Invasiveness | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Oxonic Acid | - |
dc.subject.MESH | Paclitaxel | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Stomach Neoplasms | - |
dc.subject.MESH | Tegafur | - |
dc.title | A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. | - |
dc.type | Article | - |
dc.identifier.pmid | 18813927 | - |
dc.contributor.affiliatedAuthor | 최, 진혁 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1007/s00280-008-0818-3 | - |
dc.citation.title | Cancer chemotherapy and pharmacology | - |
dc.citation.volume | 63 | - |
dc.citation.number | 6 | - |
dc.citation.date | 2009 | - |
dc.citation.startPage | 1083 | - |
dc.citation.endPage | 1090 | - |
dc.identifier.bibliographicCitation | Cancer chemotherapy and pharmacology, 63(6). : 1083-1090, 2009 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.relation.journalid | J003445704 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.